ALFA Finder
| Shares Acquired | 2.48 Cr9.12% Stake |
|---|---|
| Market Cap | ₹21,248 CrMid-cap Pharma |
| Revenue TTM | ₹5,632 CrTrailing 12 Months |
| P/E Ratio | 32.08xSector: 50.35x |
Key highlights
- Acquisition of 2,48,80,342 equity shares on September 16, 2026
- Stake in the company increased by 9.12 percentage points in a single transaction
- Total post-acquisition holding reached 3,41,21,103 shares, or 12.51% of capital
- Transaction executed through open market purchase
- Company reported 22.04% YoY revenue growth in the June 2026 quarter
What the Promoters Bought
Uma Devi Chigurupati, belonging to the promoter group of Granules India Limited, acquired 2,48,80,342 equity shares of the company on September 16, 2026. This transaction was executed through the open market, representing approximately 9.12% of the company's total voting capital at the time of the transaction. The acquisition follows a period of institutional reshuffling in the company's shareholding structure.
The total number of shares acquired matches the specific disclosure requirements under Regulation 29(2) of the SEBI Regulations, 2011, reflecting a direct purchase of shares carrying voting rights.
Shareholding Picture
Prior to this transaction, Uma Devi Chigurupati held 92,40,761 equity shares, accounting for a 3.81% stake in the target company. Following the open market purchase, her total holding has risen to 3,41,21,103 shares, representing 12.51% of the post-acquisition equity share capital. The filing indicates that the total voting capital of the company increased from Rs.
24.77 crore to Rs. 27.27 crore during this period, suggesting recent capital adjustments. No shares were reported as pledged or otherwise encumbered by the acquirer in the disclosed documentation, maintaining a zero-pledge position for this specific holding.
Business Overview
Granules India is a vertically integrated pharmaceutical manufacturer with a global footprint across more than 80 countries. Headquartered in Hyderabad, the company maintains a dominant position in high-volume molecules, including Paracetamol, Metformin, and Ibuprofen. Its business model spans the entire value chain from Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to Finished Dosages (FDs).
The company operates eight manufacturing facilities and recently expanded its reach into the peptide segment and CDMO services through the acquisition of Switzerland-based Senn Chemicals AG, aiming to diversify into complex generics.
Financial Context
For the most recent financial period ending June 30, 2026, Granules India reported operating revenue of Rs. 1,476.77 crore, marking a 22.04% increase year-on-year. Net profit for the same quarter rose significantly by 59.77% to reach Rs.
179.96 crore. The company maintains a TTM price-to-earnings (P/E) ratio of 32.08, compared to an industry average of 48.26. With a market capitalization of approximately Rs.
21,248.58 crore, the firm has demonstrated a trailing twelve-month net profit of Rs. 662.35 crore. Technical indicators show a Day RSI of 47.7, placing the stock in a neutral momentum zone.
| Share price | ₹857.5 |
|---|---|
| Market capitalisation | ₹21,248.58 Cr |
| Revenue (annual) | ₹5,365.64 Cr |
| Net profit (annual) | ₹595.02 Cr |
| Revenue (latest quarter) | ₹1,476.77 Cr+0.42% vs previous quarter |
| Net profit (latest quarter) | ₹179.96 Cr-10.72% vs previous quarter |
| P/E (TTM) | 32.08×Sector 50.35× |
| Promoter holding | 37.39%-0.63% QoQ |
| FII holding | 20.29%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Granules India Limited announcing the acquisition of shares by promoter Uma Devi Chigurupati. Market figures from a third-party data provider.
